Summary Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor with a wide variety of applications in the clinic. In early phase I studies the continuous intravenous (c.i.) route of administration was often used. Later it was shown that subcutaneous (s.c.) administration was also effective. The optimal route of administration remains, however, poorly defined, and no studies have made a direct comparison between these two routes of administration. We treated patients with advanced breast cancer with moderately high-dose doxorubicin and cylophosphamide and GM-CSF. The first 14 patients received GM-CSF by c.i, while subsequently 47 patients received it s.c. Comparison between the two groups showed that c.i. GM-CSF was more toxic in several respects. There was a higher need for erythrocyte and platelet transfusions and a significant deterioration in the performance status. This study indicates that subcutaneous GM-CSF is the preferred route of administration. Randomised trials are, however, needed to confirm these conclusions.
Granulocyte -macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor that stimulates the proliferation, maturation and functional properties of neutrophils, monocytes/macrophages and eosinophils (Ruef, 1990) . A wide variety of therapeutic applications have evolved for this cytokine. It facilitates haematopoietic recovery after cytotoxic therapy (Harmenberg, 1994) , and some trials also showed a reduction in the incidence of neutropenic fever (Gerhartz et al., 1993; Kaplan et al., 1991) . In the setting of bone marrow transplantation or peripheral blood progenitor cell transplantation GM-CSF is used either to shorten the time to engraftment or for the mobilisation of peripheral blood progenitor cells (Nemunaitis et al., 1991; Gianni et al., 1989) .
Several phase I studies showed that the biological activity of GM-CSF in man is clearly dose dependent and that effective doses are in the range of 1 to 20 ,g kg-' day-1 (Brandt et al., 1988; Antman et al., 1988; Groopman et al., 1987; Steward et al., 1989; Vadhan-Raj et al., 1987) . In these studies GM-CSF was administered by intravenous (i.v.) infusions of different duration, of which the 24 h continuous infusion (c.i.) has been the most widely used. The optimal dose and route of administration, however, remains poorly defined, but certain data suggest that the dose might be in the range of 250 Mg m-2 day-' (approximately 6 ,ug kg-' day-1) (Edmonson et al., 1989 ). Lieschke et al. (1989 were the first to show that the subcutaneous (s.c.) route of administration at dosages of 3-15 ,ug kg-' was also effective at inducing leucocytosis and was tolerated well by the patients.
No studies have made a direct comparison between c.i. and s.c. GM-CSF. Comparison between studies is complicated because different patient populations and different concomitant therapies would be expected to influence the response to GM-CSF. We performed a phase II study in which we treated patients with advanced breast cancer with a dose-intensive regimen of doxorubicin and cyclophosphamide in combination with GM-CSF. Initially a pilot study was done to establish the dose for this regimen (Hoekman et al., 1991a Clinical and laboratory monitoring While on treatment, all patients had a medical history, physical examination, baseline laboratory tests, chest radiograph and ECG before each cycle. Patients had a physical examination weekly. Between cycles they were asked to record their axillary temperature twice daily and to note any specific complaints. Full blood counts, including differential cell counts, were performed three times a week. Biochemical analysis was carried out weekly. LVEF was performed every second cycle and before the sixth cycle. Tumour response was evaluated before each cycle for patients with locally advanced 
Results
The characteristics of the 61 entered patients, the number of chemotherapy cycles, the dose intensity and total dose of chemotherapy in the different treatment groups are depicted in Table I . Figure 2 ). Platelet counts < 10 x 109 I-' were observed on 11 and 22 occasions during 58 c.i. cycles and 256 s.c. cycles respectively (P=0.04).
Erythrocyte transfusions and platelet transfusions were given mainly in later cycles (Table II) Comparative data for non-haematological toxicity are shown in Table III 
Discussion
This study, although not randomised, indicates that c.i. GM-CSF is more toxic in several respects compared with s.c. GM-CSF. Erythrocyte and platelet transfusions were needed more often with c.i. GM-CSF and there was a significant difference in deterioration of the performance status of the patients.
Both routes of administration of GM-CSF were equally effective as far as recovery of neutrophils is concerned. Mean platelet values were lower in the group receiving c.i. GM-CSF, and there was a trend for more platelet transfusions, although this did not reach significance. We did not change the policy of platelet transfusion during the study. The effect of GM-CSF on platelet counts has varied in reported studies from no effects (Brandt et al., 1988; Groopman et al., 1987; Antin et al., 1988) to an increase in recovery of platelets (Vadhan-Raj et al., 1987 . GM-CSF might induce the production of interleukin-6 (De Vries et al., 1991), which can stimulate thrombopoiesis (Hill, 1990) . Maybe with the s.c. administration this is more pronounced, because GM-CSF is injected into the skin, where accessory cells bearing GM-CSF receptors are present. These cells could then be responsible for the generation of secondary cytokines, such as interleukin-6, which can in part compensate for the suppression of thrombopoiesis. Erythrocyte infusions were also required more often in the c.i. GM-CSF group. Indications for blood transfusions did not change during the study. A cumulative anaemia has been previously described during the use of GM-CSF (Ardizzoni et al., 1994; O'Shaugnessy et al., 1994; Suderland, 1991) , but this marked difference in transfusion requirement has not been reported before. A probable explanation could be that tumour necrosis factor (TNF), which is an inhibitor of erythropoiesis (Rusten, 1995) and whose production is stimulated by GM-CSF (Sisson, 1988) is released for a prolonged period or in higher concentrations when GM-CSF is administered by the c.i. route.
Neutropenic fever judged to require intravenous antibiotics occurred more often in the group receiving c.i. GM-CSF. A possible explanation can be that our ability to discern whether fever was due to infection or to GM-CSF improved as the study progressed. Another explanation may be the presence of the Port-A-Cath, although the percentage of patients with a positive blood culture was not different between the two groups.
Various other non-haematological side-effects were observed. In three out of 14 patients who received c.i. GM-CSF a subclavian vein thrombosis developed. This complication has been described by others as well (Antman et al., 1988) , and probably results from the release ofTNF, which is an initiator of the coagulation cascade (Nawroth, 1986) . There was a noticeable difference in the incidence of stomatitis which was worse in the c.i. GM-CSF group. This occurred despite the fact that there were no significant differences in neutrophil nadir and duration of neutropenia, which usually parallels the course of stomatitis (Lockhart, 1979) . Liver enzyme disturbances were equal in both groups. It seems that this side-effect is correlated with the dose and not with the route of administration of GM-CSF (Cebon et al., 1992) . Erythematous reactions at injection sites have been described in several patients using s.c. GM-CSF (Lieschke et al., 1989) . In our group it was recorded in 38% of patients. The symptoms could generally be relieved with antihistamines. Earlier we reported on thyroid dysfunction during c.i. GM-CSF treatment in two patients with pre-existing thyroid antibodies (Hoekman et al., 1991b) . In our subsequent patients with s.c. GM-CSF we did not observe this phenomenon.
General weakness resulting in a decline in performance status was significantly worse in patients receiving c.i. GM-CSF. The reason is unclear. It is known that the side-effects of GM-CSF are in part mediated by the release of secondary cytokines such as TNF and interleukin-6 (De Vries et al., 1991; Stehle et al., 1990) . The efficacy of GM-CSF seems to correlate with the duration for which serum levels are maintained above 1 ng ml-' (Cebon et al., 1988 GM-CSF administered by c.i. is still used on several occasions (Bishop et al., 1994; Gordon et al., 1994) . There are situations where the s.c. administration is not attractive, for instance during prolonged and severe thrombocytopenia, but one should bear in mind that c.i. GM-CSF is accompanied by more side-effects. In our study there was no significant difference in treatment delay or in discontinuation of therapy between patients receiving c.i. GM-CSF or s.c. GM-CSF. One can imagine, however, that with such a difference in toxicity profile c.i. GM-CSF might have a negative effect on the delivered chemotherapy dose intensity, which seems to be an important determinant of the outcome in several clinical situations.
This study indicates that the s.c. route of administration of GM-CSF is to be preferred over the c.i. route. These results warrant further study in a randomised trial.
